

Vlad Ratziu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3856547/publications.pdf>

Version: 2024-02-01

186
papers

21,204
citations

26630

56
h-index

10445

139
g-index

192
all docs

192
docs citations

192
times ranked

15208
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 1 | A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. <i>Journal of Hepatology</i> , 2020, 73, 202-209. | 3.7 | 2,171 |
| 2 | MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. <i>Gastroenterology</i> , 2020, 158, 1999-2014.e1. | 1.3 | 1,840 |
| 3 | Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. <i>Lancet, The</i> , 2001, 357, 1069-1075. | 13.7 | 1,316 |
| 4 | Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030. <i>Journal of Hepatology</i> , 2018, 69, 896-904. | 3.7 | 1,157 |
| 5 | Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor α and δ , Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening. <i>Gastroenterology</i> , 2016, 150, 1147-1159.e5. | 1.3 | 847 |
| 6 | A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. <i>New England Journal of Medicine</i> , 2021, 384, 1113-1124. | 27.0 | 833 |
| 7 | Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. <i>Lancet, The</i> , 2019, 394, 2184-2196. | 13.7 | 818 |
| 8 | NASH limits anti-tumour surveillance in immunotherapy-treated HCC. <i>Nature</i> , 2021, 592, 450-456. | 27.8 | 649 |
| 9 | A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis. <i>Hepatology</i> , 2018, 67, 1754-1767. | 7.3 | 528 |
| 10 | Age as a Confounding Factor for the Accurate Non-Invasive Diagnosis of Advanced NAFLD Fibrosis. <i>American Journal of Gastroenterology</i> , 2017, 112, 740-751. | 0.4 | 524 |
| 11 | TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease. <i>Nature Communications</i> , 2014, 5, 4309. | 12.8 | 478 |
| 12 | A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver. <i>Journal of Hepatology</i> , 2013, 59, 550-556. | 3.7 | 421 |
| 13 | Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease. <i>BMC Gastroenterology</i> , 2006, 6, 6. | 2.0 | 378 |
| 14 | Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. <i>Hepatology</i> , 2013, 58, 1941-1952. | 7.3 | 355 |
| 15 | NAFLD and liver transplantation: Current burden and expected challenges. <i>Journal of Hepatology</i> , 2016, 65, 1245-1257. | 3.7 | 352 |
| 16 | Advancing the global public health agenda for NAFLD: a consensus statement. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2022, 19, 60-78. | 17.8 | 330 |
| 17 | From NAFLD in clinical practice to answers from guidelines. <i>Journal of Hepatology</i> , 2013, 59, 859-871. | 3.7 | 304 |
| 18 | A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH. <i>New England Journal of Medicine</i> , 2021, 385, 1547-1558. | 27.0 | 284 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 19 | Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort†. <i>Journal of Hepatology</i> , 2020, 73, 505-515. | 3.7 | 279 |
| 20 | Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS). <i>Lancet Infectious Diseases</i> , The, 2015, 15, 397-404. | 9.1 | 267 |
| 21 | Simtuzumab Is Ineffective for Patients With Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis. <i>Gastroenterology</i> , 2018, 155, 1140-1153. | 1.3 | 253 |
| 22 | Current efforts and trends in the treatment of NASH. <i>Journal of Hepatology</i> , 2015, 62, S65-S75. | 3.7 | 228 |
| 23 | Cenicriviroc Treatment for Adults With Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study. <i>Hepatology</i> , 2020, 72, 892-905. | 7.3 | 227 |
| 24 | The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials. <i>Hepatology</i> , 2019, 70, 1913-1927. | 7.3 | 226 |
| 25 | Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis. <i>Science Translational Medicine</i> , 2020, 12, . | 12.4 | 205 |
| 26 | Efficacy and safety study of cenicriviroc for the treatment of non-alcoholic steatohepatitis in adult subjects with liver fibrosis: CENTAUR Phase 2b study design. <i>Contemporary Clinical Trials</i> , 2016, 47, 356-365. | 1.8 | 178 |
| 27 | Concordance of sustained virological response 4, 12, and 24 weeks post-treatment with sofosbuvir-containing regimens for hepatitis C virus. <i>Hepatology</i> , 2015, 61, 41-45. | 7.3 | 173 |
| 28 | Liver fibrosis evaluation using real-time shear wave elastography: Applicability and diagnostic performance using methods without a gold standard. <i>Journal of Hepatology</i> , 2013, 58, 928-935. | 3.7 | 151 |
| 29 | Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis. <i>Journal of Hepatology</i> , 2021, 75, 770-785. | 3.7 | 149 |
| 30 | A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 970-985. | 8.1 | 142 |
| 31 | Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis C. <i>Journal of Hepatology</i> , 2013, 59, 675-683. | 3.7 | 134 |
| 32 | Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science. <i>Hepatology</i> , 2018, 67, 2001-2012. | 7.3 | 125 |
| 33 | A cross-sectional study of the public health response to non-alcoholic fatty liver disease in Europe. <i>Journal of Hepatology</i> , 2020, 72, 14-24. | 3.7 | 123 |
| 34 | The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge?. <i>Journal of Hepatology</i> , 2022, 76, 771-780. | 3.7 | 114 |
| 35 | Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 193-203. | 3.7 | 112 |
| 36 | REGENERATE: Design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis. <i>Contemporary Clinical Trials</i> , 2019, 84, 105803. | 1.8 | 105 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | Comparison of fatty liver index with noninvasive methods for steatosis detection and quantification. <i>World Journal of Gastroenterology</i> , 2013, 19, 57. | 3.3 | 104 |
| 38 | Development and Validation of Hepamet Fibrosis Scoring System—A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 216-225.e5. | 4.4 | 104 |
| 39 | Portal myofibroblasts promote vascular remodeling underlying cirrhosis formation through the release of microparticles. <i>Hepatology</i> , 2015, 61, 1041-1055. | 7.3 | 102 |
| 40 | Staging chronic hepatitis C in seven categories using fibrosis biomarker (FibroTest [®]) and transient elastography (FibroScan [®]). <i>Journal of Hepatology</i> , 2014, 60, 706-714. | 3.7 | 101 |
| 41 | TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a Trial. <i>Gastroenterology</i> , 2021, 161, 1475-1486. | 1.3 | 101 |
| 42 | Fatty liver is an independent predictor of early carotid atherosclerosis. <i>Journal of Hepatology</i> , 2016, 65, 95-102. | 3.7 | 91 |
| 43 | Rates of and Factors Associated With Placebo Response in Trials of Pharmacotherapies for Nonalcoholic Steatohepatitis: Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 616-629.e26. | 4.4 | 91 |
| 44 | Statins, antidiabetic medications and liver histology in patients with diabetes with non-alcoholic fatty liver disease. <i>BMJ Open Gastroenterology</i> , 2016, 3, e000075. | 2.7 | 90 |
| 45 | Performance of the PRO-C3 collagen neo-epitope biomarker in non-alcoholic fatty liver disease. <i>JHEP Reports</i> , 2019, 1, 188-198. | 4.9 | 86 |
| 46 | Inhibition of receptor-interacting protein kinase 1 improves experimental non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2020, 72, 627-635. | 3.7 | 84 |
| 47 | A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial. <i>Contemporary Clinical Trials</i> , 2020, 88, 105889. | 1.8 | 80 |
| 48 | Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis in five European countries in 2018: A cost-of-illness analysis. <i>Liver International</i> , 2021, 41, 1227-1242. | 3.9 | 76 |
| 49 | Complexity of ballooned hepatocyte feature recognition: Defining a training atlas for artificial intelligence-based imaging in NAFLD. <i>Journal of Hepatology</i> , 2022, 76, 1030-1041. | 3.7 | 74 |
| 50 | The European NAFLD Registry: A real-world longitudinal cohort study of nonalcoholic fatty liver disease. <i>Contemporary Clinical Trials</i> , 2020, 98, 106175. | 1.8 | 71 |
| 51 | Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study. <i>Journal of Hepatology</i> , 2022, 76, 536-548. | 3.7 | 66 |
| 52 | Breakthroughs in therapies for NASH and remaining challenges. <i>Journal of Hepatology</i> , 2022, 76, 1263-1278. | 3.7 | 66 |
| 53 | Validation of liver fibrosis biomarker (FibroTest) for assessing liver fibrosis progression: Proof of concept and first application in a large population. <i>Journal of Hepatology</i> , 2012, 57, 541-548. | 3.7 | 65 |
| 54 | Significant Variations in Elastometry Measurements Made Within Short-term in Patients With Chronic Liver Diseases. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 763-771.e6. | 4.4 | 65 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 55 | Defining Improvement in Nonalcoholic Steatohepatitis for Treatment Trial Endpoints: Recommendations From the Liver Forum. <i>Hepatology</i> , 2019, 70, 1841-1855. | 7.3 | 64 |
| 56 | Systematic review of bariatric surgery liver biopsies clarifies the natural history of liver disease in patients with severe obesity. <i>Gut</i> , 2017, 66, 1688-1696. | 12.1 | 59 |
| 57 | Why Do So Many Nonalcoholic Steatohepatitis Trials Fail?. <i>Gastroenterology</i> , 2023, 165, 5-10. | 1.3 | 59 |
| 58 | Applicability and precautions of use of liver injury biomarker FibroTest. A reappraisal at 7 years of age. <i>BMC Gastroenterology</i> , 2011, 11, 39. | 2.0 | 58 |
| 59 | Pharmacological agents for NASH. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2013, 10, 676-685. | 17.8 | 58 |
| 60 | A critical review of endpoints for non-cirrhotic NASH therapeutic trials. <i>Journal of Hepatology</i> , 2018, 68, 353-361. | 3.7 | 58 |
| 61 | RIPK3 acts as a lipid metabolism regulator contributing to inflammation and carcinogenesis in non-alcoholic fatty liver disease. <i>Gut</i> , 2021, 70, 2359-2372. | 12.1 | 56 |
| 62 | Macrophage scavenger receptor 1 mediates lipid-induced inflammation in non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2022, 76, 1001-1012. | 3.7 | 54 |
| 63 | Diagnostic Accuracy of Noninvasive Markers of Steatosis, NASH, and Liver Fibrosis in HIV-Monoinfected Individuals at Risk of Nonalcoholic Fatty Liver Disease (NAFLD): Results From the ECHAM Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 80, e86-e94. | 2.1 | 53 |
| 64 | Cost of non-alcoholic steatohepatitis in Europe and the USA: The GAIN study. <i>JHEP Reports</i> , 2020, 2, 100142. | 4.9 | 53 |
| 65 | Expert Panel Review to Compare FDA and EMA Guidance on Drug Development and Endpoints in Nonalcoholic Steatohepatitis. <i>Gastroenterology</i> , 2022, 162, 680-688. | 1.3 | 53 |
| 66 | Clinical validation of the FLIP algorithm and the SAF score in patients with non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2020, 72, 828-838. | 3.7 | 52 |
| 67 | The conundrum of cryptogenic cirrhosis: Adverse outcomes without treatment options. <i>Journal of Hepatology</i> , 2018, 69, 1365-1370. | 3.7 | 51 |
| 68 | EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study. <i>Journal of Hepatology</i> , 2022, 76, 506-517. | 3.7 | 49 |
| 69 | The times they are a-changin' (for NAFLD as well). <i>Journal of Hepatology</i> , 2020, 73, 1307-1309. | 3.7 | 45 |
| 70 | Randomized Study of Asunaprevir plus Pegylated Interferon- α and Ribavirin for Previously Untreated Genotype 1 Chronic Hepatitis C. <i>Antiviral Therapy</i> , 2013, 18, 885-893. | 1.0 | 44 |
| 71 | Staging chronic hepatitis B into seven categories, defining inactive carriers and assessing treatment impact using a fibrosis biomarker (FibroTest $\text{\textcircled{A}}$) and elastography (FibroScan $\text{\textcircled{A}}$). <i>Journal of Hepatology</i> , 2014, 61, 994-1003. | 3.7 | 42 |
| 72 | Prevalence of steatosis and insulin resistance in patients with chronic hepatitis B compared with chronic hepatitis C and non-alcoholic fatty liver disease. <i>European Journal of Internal Medicine</i> , 2015, 26, 30-36. | 2.2 | 42 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 73 | Relationship Among Fatty Liver, Specific and Multipleâ€Site Atherosclerosis, and 10â€Year Framingham Score. <i>Hepatology</i> , 2019, 69, 1453-1463. | 7.3 | 41 |
| 74 | Obeticholic Acid Impact on Quality of Life in Patients With Nonalcoholic Steatohepatitis: REGENERATE 18-Month Interim Analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2050-2058.e12. | 4.4 | 41 |
| 75 | Liver Stiffness by Transient Elastography to Detect Portoâ€Sinusoidal Vascular Liver Disease With Portal Hypertension. <i>Hepatology</i> , 2021, 74, 364-378. | 7.3 | 40 |
| 76 | Hepatic stellate cell hypertrophy is associated with metabolic liver fibrosis. <i>Scientific Reports</i> , 2020, 10, 3850. | 3.3 | 39 |
| 77 | Non-alcoholic fatty liver â€ Perhaps not so benign. <i>Journal of Hepatology</i> , 2015, 62, 1002-1004. | 3.7 | 38 |
| 78 | Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 454-465. | 8.1 | 36 |
| 79 | Novel Pharmacotherapy Options for NASH. <i>Digestive Diseases and Sciences</i> , 2016, 61, 1398-1405. | 2.3 | 35 |
| 80 | The Impact of Obesity and Metabolic Syndrome on Chronic Hepatitis B and Drug-Induced Liver Disease. <i>Clinics in Liver Disease</i> , 2014, 18, 165-178. | 2.1 | 34 |
| 81 | Nonâ€pharmacological interventions in nonâ€alcoholic fatty liver disease patients. <i>Liver International</i> , 2017, 37, 90-96. | 3.9 | 34 |
| 82 | Fecal Microbiota Transplant from Human to Mice Gives Insights into the Role of the Gut Microbiota in Non-Alcoholic Fatty Liver Disease (NAFLD). <i>Microorganisms</i> , 2021, 9, 199. | 3.6 | 33 |
| 83 | Bone morphogenetic protein 8B promotes the progression of non-alcoholic steatohepatitis. <i>Nature Metabolism</i> , 2020, 2, 514-531. | 11.9 | 31 |
| 84 | Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease. <i>JHEP Reports</i> , 2022, 4, 100477. | 4.9 | 31 |
| 85 | Portal fibroblasts with mesenchymal stem cell features form a reservoir of proliferative myofibroblasts in liver fibrosis. <i>Hepatology</i> , 2022, 76, 1360-1375. | 7.3 | 30 |
| 86 | Treatment of NASH with ursodeoxycholic acid: Pro. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2012, 36, S41-S45. | 1.5 | 28 |
| 87 | Longâ€term prognostic value of the FibroTest in patients with nonâ€alcoholic fatty liver disease, compared to chronic hepatitis C, B, and alcoholic liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 1117-1127. | 3.7 | 28 |
| 88 | Recommendations for Management and Treatment of Nonalcoholic Steatohepatitis. <i>Transplantation</i> , 2019, 103, 28-38. | 1.0 | 28 |
| 89 | Telaprevir Activity in Treatment-Naive Patients Infected Hepatitis C Virus Genotype 4: A Randomized Trial. <i>Journal of Infectious Diseases</i> , 2013, 208, 1000-1007. | 4.0 | 27 |
| 90 | European â€NAFLD Preparedness Indexâ€ â€ Is Europe ready to meet the challenge of fatty liver disease?. <i>JHEP Reports</i> , 2021, 3, 100234. | 4.9 | 27 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 91 | Comparison of ADAPT, FIB-4 and APRI as non-invasive predictors of liver fibrosis and NASH within the CENTAUR screening population. <i>Journal of Hepatology</i> , 2021, 75, 1292-1300. | 3.7 | 27 |
| 92 | Nonalcoholic Fatty Liver Disease Increases the Risk of Hepatocellular Carcinoma in Patients With Alcohol-Associated Cirrhosis Awaiting Liver Transplants. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 992-999.e2. | 4.4 | 26 |
| 93 | Efficacy and safety of PXL770, a direct AMP kinase activator, for the treatment of non-alcoholic fatty liver disease (STAMP-NAFLD): a randomised, double-blind, placebo-controlled, phase 2a study. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 889-902. | 8.1 | 26 |
| 94 | Real-Time Shear Wave versus Transient Elastography for Predicting Fibrosis: Applicability, and Impact of Inflammation and Steatosis. A Non-Invasive Comparison. <i>PLoS ONE</i> , 2016, 11, e0163276. | 2.5 | 26 |
| 95 | Randomized trial of asunaprevir plus peginterferon alfa and ribavirin for previously untreated genotype 1 or 4 chronic hepatitis C. <i>Journal of Hepatology</i> , 2014, 61, 1220-1227. | 3.7 | 25 |
| 96 | Semaglutide for the treatment of non-alcoholic steatohepatitis: Trial design and comparison of non-invasive biomarkers. <i>Contemporary Clinical Trials</i> , 2020, 97, 106174. | 1.8 | 25 |
| 97 | Yet more evidence that MAFLD is more than a name change. <i>Journal of Hepatology</i> , 2021, 74, 977-979. | 3.7 | 25 |
| 98 | Burden of liver disease progression in hospitalized patients with type 2 diabetes mellitus. <i>Journal of Hepatology</i> , 2022, 76, 265-274. | 3.7 | 24 |
| 99 | Dihydroceramides in Triglyceride-Enriched VLDL Are Associated with Nonalcoholic Fatty Liver Disease Severity in Type 2 Diabetes. <i>Cell Reports Medicine</i> , 2020, 1, 100154. | 6.5 | 23 |
| 100 | Persistence of severe liver fibrosis despite substantial weight loss with bariatric surgery. <i>Hepatology</i> , 2022, 76, 456-468. | 7.3 | 22 |
| 101 | Real-World Burden of Nonalcoholic Steatohepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1020-1029.e7. | 4.4 | 21 |
| 102 | Increased serum miR-193a-5p during non-alcoholic fatty liver disease progression: Diagnostic and mechanistic relevance. <i>JHEP Reports</i> , 2022, 4, 100409. | 4.9 | 20 |
| 103 | Impact of Sarcopenia on the Severity of the Liver Damage in Patients With Non-alcoholic Fatty Liver Disease. <i>Frontiers in Nutrition</i> , 2021, 8, 774030. | 3.7 | 20 |
| 104 | Is mipomersen ready for clinical implementation? A transatlantic dilemma. <i>Current Opinion in Lipidology</i> , 2013, 24, 301-306. | 2.7 | 19 |
| 105 | Hepatocellular Carcinoma Management in Nonalcoholic Fatty Liver Disease Patients. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2016, 39, 428-432. | 1.3 | 19 |
| 106 | Initial assessment and ongoing monitoring of lysosomal acid lipase deficiency in children and adults: Consensus recommendations from an international collaborative working group. <i>Molecular Genetics and Metabolism</i> , 2020, 129, 59-66. | 1.1 | 17 |
| 107 | Peptide-based urinary monitoring of fibrotic nonalcoholic steatohepatitis by mass-barcoded activity-based sensors. <i>Science Translational Medicine</i> , 2021, 13, eabe8939. | 12.4 | 17 |
| 108 | Performances of Elasto-FibroTest®, a combination between FibroTest® and liver stiffness measurements for assessing the stage of liver fibrosis in patients with chronic hepatitis C. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2012, 36, 455-463. | 1.5 | 16 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 109 | Hepatic molecular effects of rosiglitazone in human nonalcoholic steatohepatitis suggest long-term proinflammatory damage. <i>Hepatology Research</i> , 2014, 44, 1241-1247. | 3.4 | 16 |
| 110 | Back to Byzance: Querelles byzantines over NASH and fibrosis. <i>Journal of Hepatology</i> , 2017, 67, 1134-1136. | 3.7 | 16 |
| 111 | Diagnostic performance of a new noninvasive test for nonalcoholic steatohepatitis using a simplified histological reference. <i>European Journal of Gastroenterology and Hepatology</i> , 2018, 30, 569-577. | 1.6 | 15 |
| 112 | LCR1 and LCR2, two multi-analyte blood tests to assess liver cancer risk in patients without or with cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 308-320. | 3.7 | 15 |
| 113 | Attribution of Nonalcoholic Steatohepatitis as an Etiology of Cirrhosis for Clinical Trials Eligibility: Recommendations From the Multi-stakeholder Liver Forum. <i>Gastroenterology</i> , 2020, 159, 422-427.e1. | 1.3 | 15 |
| 114 | Reliability of histologic assessment for NAFLD and development of an expanded NAFLD activity score. <i>Hepatology</i> , 2022, 76, 1150-1163. | 7.3 | 15 |
| 115 | Starting the battle to control non-alcoholic steatohepatitis. <i>Lancet, The</i> , 2015, 385, 922-924. | 13.7 | 14 |
| 116 | Validation of AshTest as a Non-Invasive Alternative to Transjugular Liver Biopsy in Patients with Suspected Severe Acute Alcoholic Hepatitis. <i>PLoS ONE</i> , 2015, 10, e0134302. | 2.5 | 14 |
| 117 | SILEN-C3, a Phase 2 Randomized Trial with Faldaprevir plus Pegylated Interferon Î±-2a and Ribavirin in Treatment-Naive Hepatitis C Virus Genotype 1-Infected Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 3429-3436. | 3.2 | 13 |
| 118 | Impact of sorafenib dosing on outcome from the European patient subset of the GIDEON study. <i>Future Oncology</i> , 2015, 11, 2553-2562. | 2.4 | 13 |
| 119 | Serum apolipoprotein A1 and haptoglobin, in patients with suspected drug-induced liver injury (DILI) as biomarkers of recovery. <i>PLoS ONE</i> , 2017, 12, e0189436. | 2.5 | 13 |
| 120 | Impact of steatosis and inflammation definitions on the performance of NASH tests. <i>European Journal of Gastroenterology and Hepatology</i> , 2018, 30, 384-391. | 1.6 | 13 |
| 121 | Vitamin D in addition to peg-interferon-alpha/ribavirin in chronic hepatitis C virus infection: ANRS-HC25-VITAVIC study. <i>World Journal of Gastroenterology</i> , 2015, 21, 5647. | 3.3 | 13 |
| 122 | Predictive value of liver damage for severe early complications and survival after heart transplantation: A retrospective analysis. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2018, 42, 416-426. | 1.5 | 12 |
| 123 | The diagnostic performance of a simplified blood test (SteatoTest-2) for the prediction of liver steatosis. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 393-402. | 1.6 | 12 |
| 124 | NAFLD: The evolving landscape. <i>Journal of Hepatology</i> , 2018, 68, 227-229. | 3.7 | 11 |
| 125 | Identification of Patients with Advanced Fibrosis Due to Nonalcoholic Fatty Liver Disease: Considerations for Best Practice. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2020, 29, 235-245. | 0.9 | 11 |
| 126 | Anti-hepatitis C virus antibody detection in oral fluid: Influence of human immunodeficiency virus co-infection. <i>Journal of Clinical Virology</i> , 2013, 58, 385-390. | 3.1 | 10 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 127 | Non-Alcoholic Fatty Liver Disease: Diagnosis and Investigation. <i>Digestive Diseases</i> , 2014, 32, 586-596. | 1.9 | 10 |
| 128 | Variability in definitions of transaminase upper limit of the normal impacts the APRI performance as a biomarker of fibrosis in patients with chronic hepatitis C: "APRI est finit". <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2014, 38, 432-439. | 1.5 | 10 |
| 129 | Performance of serum apolipoprotein-A1 as a sentinel of Covid-19. <i>PLoS ONE</i> , 2020, 15, e0242306. | 2.5 | 10 |
| 130 | Awareness of the severity of liver disease re-examined using software-combined biomarkers of liver fibrosis and necroinflammatory activity. <i>BMJ Open</i> , 2015, 5, e010017. | 1.9 | 9 |
| 131 | Screening HIV Patients at Risk for NAFLD Using MRI-PDFF and Transient Elastography: A European Multicenter Prospective Study. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 713-722.e3. | 4.4 | 9 |
| 132 | When the journey from obesity to cirrhosis takes an early start. <i>Journal of Hepatology</i> , 2016, 65, 249-251. | 3.7 | 8 |
| 133 | The painful reality of end-stage liver disease in NASH. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 8-10. | 8.1 | 8 |
| 134 | Performance of liver biomarkers, in patients at risk of nonalcoholic steato-hepatitis, according to presence of type-2 diabetes. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, 32, 998-1007. | 1.6 | 8 |
| 135 | Early Health Technology Assessment during Nonalcoholic Steatohepatitis Drug Development: A Two-Round, Cross-Country, Multicriteria Decision Analysis. <i>Medical Decision Making</i> , 2020, 40, 830-845. | 2.4 | 8 |
| 136 | Clinical Interest of Serum Alpha-2 Macroglobulin, Apolipoprotein A1, and Haptoglobin in Patients with Non-Alcoholic Fatty Liver Disease, with and without Type 2 Diabetes, before or during COVID-19. <i>Biomedicines</i> , 2022, 10, 699. | 3.2 | 7 |
| 137 | An international survey on patterns of practice in NAFLD and expectations for therapies "The POP-NEXT project. <i>Hepatology</i> , 2022, 76, 1766-1777. | 7.3 | 7 |
| 138 | External validation of LCR1-LCR2, a multivariable HCC risk calculator, in patients with chronic HCV. <i>JHEP Reports</i> , 2021, 3, 100298. | 4.9 | 6 |
| 139 | Real-life Perception and Practice Patterns of NAFLD/NASH in Romania: Results of a Survey Completed by 102 Board-certified Gastroenterologists. <i>Journal of Gastrointestinal and Liver Diseases</i> , 2020, 25, 183-189. | 0.9 | 5 |
| 140 | Targeting non-alcoholic fatty liver disease through 11- β HSD1 inhibition. <i>Lancet Diabetes and Endocrinology</i> , 2014, 2, 354-356. | 11.4 | 4 |
| 141 | Improving NASH with a little help from thymomimetics. <i>Lancet</i> , 2019, 394, 1970-1972. | 13.7 | 4 |
| 142 | A New, Non-Invasive Scale for Steatosis Developed Using Real-World Data From Russian Outpatients to Aid in the Diagnosis of Non-Alcoholic Fatty Liver Disease. <i>Advances in Therapy</i> , 2020, 37, 4627-4640. | 2.9 | 4 |
| 143 | Introducing the Expert Opinion series. <i>Journal of Hepatology</i> , 2020, 73, 5. | 3.7 | 4 |
| 144 | From the Editor's Desk . <i>Journal of Hepatology</i> , 2021, 74, 1-4. | 3.7 | 4 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 145 | Arterial hypertension as an uninvited player in hepatic stiffness?. American Journal of Physiology - Renal Physiology, 2016, 311, G942-G944. | 3.4 | 3 |
| 146 | External validation of an algorithm combining multi-analyte blood tests (FibroTest-LCR1-LCR2) to identify subjects at risk of hepatocellular carcinoma in patients with chronic liver disease. GastroHep, 2019, 1, 146-153. | 0.6 | 3 |
| 147 | From the Editor's Desk.... Journal of Hepatology, 2020, 73, 1-4. | 3.7 | 3 |
| 148 | coreNASH: Multi-stakeholder Consensus on Core Outcomes for Decision Making About Nonalcoholic Steatohepatitis Treatment. Hepatology Communications, 2021, 5, 774-785. | 4.3 | 3 |
| 149 | From the Editor's Desk.... Journal of Hepatology, 2021, 75, 1-4. | 3.7 | 3 |
| 150 | From the Editor's Desk . Journal of Hepatology, 2021, 75, 757-760. | 3.7 | 3 |
| 151 | Pharmacological agents for nonalcoholic steatohepatitis. Hepatology International, 2013, 7, 833-841. | 4.2 | 2 |
| 152 | Blood Tests to Diagnose Fibrosis or Cirrhosis in Patients With Chronic Hepatitis C Virus Infection. Annals of Internal Medicine, 2013, 159, 370. | 3.9 | 2 |
| 153 | Reply to "Establishing the independence and clinical importance of non-alcoholic fatty liver disease as a risk factor for cardiovascular disease". Journal of Hepatology, 2016, 65, 1267-1268. | 3.7 | 2 |
| 154 | Benefit of Treatment With Sebelipase-Alfa in a 63-Year-Old Patient With Advanced Liver and Atherosclerotic Disease Due to Lysosomal Acid Lipase Deficiency (LAL-D). American Journal of Gastroenterology, 2018, 113, 443-445. | 0.4 | 2 |
| 155 | Obeticholic Acid for the Treatment of Nonalcoholic Steatohepatitis. Clinical Liver Disease, 2021, 17, 398-400. | 2.1 | 2 |
| 156 | External Validation of LCR1-LCR2, a Multivariable Hepatocellular Carcinoma Risk Calculator, in a Multiethnic Cohort of Patients With Chronic Hepatitis B. , 2022, 1, 604-617. | | 2 |
| 157 | Screening studies of transient elastography and FibroTest in the general population. The Lancet Gastroenterology and Hepatology, 2017, 2, 246. | 8.1 | 1 |
| 158 | From the Editor's Desk . Journal of Hepatology, 2021, 75, 257-260. | 3.7 | 1 |
| 159 | NAFLD Phenotype in Patients With V-ATPase Proton Pump Assembly Defects. Cellular and Molecular Gastroenterology and Hepatology, 2018, 5, 415-417.e1. | 4.5 | 0 |
| 160 | Editorial: it is not a wide-open field for incretins -collateral benefits favour the use of metformin in advanced non-alcoholic steatohepatitis. Alimentary Pharmacology and Therapeutics, 2019, 50, 611-612. | 3.7 | 0 |
| 161 | From the Editor's Desk . Journal of Hepatology, 2020, 73, 1001-1004. | 3.7 | 0 |
| 162 | From the Editor's Desk . Journal of Hepatology, 2020, 73, 475-478. | 3.7 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 163 | From the Editor's Desk.... Journal of Hepatology, 2020, 73, 745-748. | 3.7 | 0 |
| 164 | Clinical endpoints are necessary in the interim analysis of REGENERATE â€“ Authors' reply. Lancet, The, 2020, 396, 663-664. | 13.7 | 0 |
| 165 | From the Editor's Deskâ€™. Journal of Hepatology, 2020, 73, 1299-1302. | 3.7 | 0 |
| 166 | From the Editor's Deskâ€™. Journal of Hepatology, 2020, 72, 1039-1042. | 3.7 | 0 |
| 167 | From the Editor's Desk.... Journal of Hepatology, 2020, 72, 597-600. | 3.7 | 0 |
| 168 | From the Editor's Deskâ€™. Journal of Hepatology, 2020, 73, 227-230. | 3.7 | 0 |
| 169 | Timing Is Everything: Improving NASH Histology in Clinical Trials Should Not Be Rushed. Hepatology, 2020, 71, 1146-1149. | 7.3 | 0 |
| 170 | From the Editor's Deskâ€™. Journal of Hepatology, 2020, 72, 379-383. | 3.7 | 0 |
| 171 | From the Editorâ€™s Deskâ€™. Journal of Hepatology, 2020, 72, 805-808. | 3.7 | 0 |
| 172 | From the Editor's Deskâ€™. Journal of Hepatology, 2021, 74, 265-268. | 3.7 | 0 |
| 173 | From the Editor's Desk.... Journal of Hepatology, 2021, 74, 493-496. | 3.7 | 0 |
| 174 | From the Editorâ€™s Desk.... Journal of Hepatology, 2021, 74, 765-768. | 3.7 | 0 |
| 175 | From the Editorâ€™s Desk.... Journal of Hepatology, 2021, 74, 1005-1008. | 3.7 | 0 |
| 176 | From the Editorâ€™s Deskâ€™. Journal of Hepatology, 2021, 74, 1277-1280. | 3.7 | 0 |
| 177 | From the Editorâ€™s Deskâ€™. Journal of Hepatology, 2021, 75, 499-502. | 3.7 | 0 |
| 178 | From the Editorâ€™s deskâ€™. Journal of Hepatology, 2021, 75, 1013-1016. | 3.7 | 0 |
| 179 | From the Editorâ€™s Desk.... Journal of Hepatology, 2021, 75, 1261-1264. | 3.7 | 0 |
| 180 | From the Editorâ€™s Desk.... Journal of Hepatology, 2022, 76, 1-4. | 3.7 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 181 | From the Editor's Desk.... Journal of Hepatology, 2022, 76, 257-260. | 3.7 | 0 |
| 182 | Reply. Hepatology, 2022, 76, E43-E43. | 7.3 | 0 |
| 183 | From the Editor's Desk.... Journal of Hepatology, 2022, 76, 491-494. | 3.7 | 0 |
| 184 | From the Editor's Desk.... Journal of Hepatology, 2022, 76, 759-762. | 3.7 | 0 |
| 185 | Reply. Hepatology, 2022, 76, E53-E53. | 7.3 | 0 |
| 186 | From the Editor's Desk.... Journal of Hepatology, 2022, 76, 991-994. | 3.7 | 0 |